126090-31-1Relevant academic research and scientific papers
Development of Chiral Ureates as Chiral Strong Br?nsted Base Catalysts
Ishikawa, Sho,Kondoh, Azusa,Terada, Masahiro
, p. 3724 - 3728 (2020/03/11)
Recently, chiral Br?nsted bases having high basicity have emerged as a powerful tool in developing new catalytic enantioselective reactions. However, such chiral strong Br?nsted base catalysts are still very scarce. Herein, we report the development of a chiral anionic Br?nsted base having a N,N′-dialkyl ureate moiety as a basic site. Its prominent catalytic activity was demonstrated in the enantioselective addition reactions of α-thioacetamides as less acidic pronucleophiles with various electrophiles. Thus, the newly developed chiral catalyst with high accessibility and structural tunability would expand the scope of viable enantioselective transformations under Br?nsted base catalysis.
New thiourea organocatalysts and their application for the synthesis of 5-(1H-indol-3-yl)methyl-2,2-dimethyl-1,3-dioxane-4,6-diones a source of chiral 3-indoylmethyl ketenes
Najda-Mocarska, Ewelina,Zakaszewska, Anna,Janikowska, Karolina,Makowiec, S?awomir
supporting information, p. 14 - 25 (2017/12/26)
The stereoselective properties of modified thiourea organocatalysts were tested in the Friedel–Crafts alkylation of indole with 5-arylidene-2,2-dimethyl-1,3-dioxane-4,6-diones, which produces chiral 5-((1H-indol-3-yl)(aryl)methyl)-2,2-dimethyl-1,3-dioxane-4,6-diones. Based on a tentative reaction mechanism for ((S)-N-benzyl-2-(3-(3,5-bis(trifluoromethyl)phenyl)thioureido)-N,3,3-trimethylbutanamide organocatalysts, modifications were applied in four selected regions. Systematic structure-stereoselectivity relationship study allowed designing the best efficient organocatalyst for the investigated Friedel–Crafts alkylation of indole with 5-arylidene-2,2-dimethyl-1,3-dioxane-4,6-diones.
NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF
-
Paragraph 1446-1451, (2015/02/18)
The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures.
NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME
-
Paragraph 3821-3824, (2015/10/05)
The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.
Efficient transamidation of primary carboxamides by in situ activation with N,N-dialkylformamide dimethyl acetals
Dineen, Thomas A.,Zajac, Matthew A.,Myers, Andrew G.
, p. 16406 - 16409 (2007/10/03)
Two protocols for the transamidation of primary amides with primary and secondary amines, forming secondary and tertiary amides, respectively, are described. Both processes employ N,N-dialkylformamide dimethyl acetals for primary amide activation, producing N-acyl-N,N-dialkylformamidines as intermediates, as widely documented in the literature. Although the latter intermediates react irreversibly with amines by amidinyl transfer, we show that in the presence of certain Lewis acid additives efficient acyl transfer occurs, providing new and useful methods for amide exchange. In one protocol for transamidation, the N-acyl-N,N-dialkylformamidine intermediates are purified by flash-column chromatography and the purified intermediates are then treated with an amine (typically, 2.5 equiv) in the presence of scandium triflate (10 mol %) in ether to form in high yields the products of transamidation. In a second procedure, N-acyl-N,N-dialkylformamidines are generated in situ and, without isolation, are subjected to transamidation in the presence of zirconium chloride (0.5 equiv) and an amine (typically 2 equiv). A variety of different primary amides and amines are found to undergo efficient transamidation using the methods described.
Tetrapeptide Tachykinin Antagonists: Synthesis and Modulation of the Physicochemical and Pharmacological Properties of a New Series of Partially Cyclic Analogs
Kucharczyk, Nathalie,Thurieau, Christophe,Paladino, Joseph,Morris, Angela D.,Bonnet, Jacqueline,et al.
, p. 1654 - 1661 (2007/10/02)
We report on the synthesis and the pharmacological properties of a new series of tachykinin antagonists based on the pseudopeptide pharmacophore cyclo which contains the 2-azabicyclooctane-3(S)-carboxylic acid (Abo) r
Studies on Neurokinin Antagonists. 2. Design and Structure-Activity Relationships of Novel Tripeptide Substance P Antagonists, Nα-α-(Nα-Acetyl-L-threonyl)-N1-formyl-D-tryptophyl>-N-methyl-N-(phenylmethyl)-L-ph
Hagiwara, Daijiro,Miyake, Hiroshi,Morimoto, Hiroshi,Murai, Masako,Fujii, Takashi,Matsuo, Masaaki
, p. 3184 - 3191 (2007/10/02)
Continuing studies on the chemical modification of the previously reported novel tripeptide SP antagonist, Nα-α-α-(tert-butyloxycarbonyl)glutaminyl>-N1-formyl-D-tryptophyl>phenylalanine benzyl ester Boc-Gln
